Articles producció científicaCiències Mèdiques Bàsiques

Critical appraisal beyond clinical guidelines for intraabdominal candidiasis

  • Dades identificatives

    Identificador:  imarina:9414315
    Autors:  Maseda, Emilio; Martin-Loeches, Ignacio; Zaragoza, Rafael; Peman, Javier; Fortun, Jesus; Grau, Santiago; Aguilar, Gerardo; Varela, Marina; Borges, Marcio; Gimenez, Maria-Jose; Rodriguez, Alejandro
    Resum:
    BackgroundRegardless of the available antifungals, intraabdominal candidiasis (IAC) mortality continues to be high and represents a challenge for clinicians.Main bodyThis opinion paper discusses alternative antifungal options for treating IAC. This clinical entity should be addressed separately from candidemia due to the peculiarity of the required penetration of antifungals into the peritoneal cavity. Intraabdominal concentrations may be further restricted in critically ill patients where pathophysiological facts alter normal drug distribution. Echinocandins are recommended as first-line treatment in guidelines for invasive candidiasis. However, considering published data, our pharmacodynamic analysis suggests the required increase of doses, postulated by some authors, to attain adequate pharmacokinetic (PK) levels in peritoneal fluid. Given the limited evidence in the literature on PK/PD-based treatments of IAC, an algorithm is proposed to guide antifungal treatment. Liposomal amphotericin B is advocated as first-line therapy in patients with sepsis/septic shock presenting candidemia or endophthalmitis, or with prior exposure to echinocandins and/or fluconazole, or with infections by Candida glabrata. Other situations and alternatives, such as new compounds or combination therapy, are also analysed.ConclusionThere is a critical need for more robust clinical trials, studies examining patient heterogeneity and surveillance of antifungal resistance to enhance patient care and optimise treatment outcomes. Such evidence will help refine the existing guidelines and contribute to a more personalised and effective approach to treating this serious medical condition. Meanwhile, it is suggested to broaden the consideration of other options, such as liposomal amphotericin B, as
  • Altres:

    Autor segons l'article: Maseda, Emilio; Martin-Loeches, Ignacio; Zaragoza, Rafael; Peman, Javier; Fortun, Jesus; Grau, Santiago; Aguilar, Gerardo; Varela, Marina; Borges, Marcio; Gimenez, Maria-Jose; Rodriguez, Alejandro
    Departament: Ciències Mèdiques Bàsiques
    Autor/s de la URV: Rodríguez Oviedo, Alejandro Hugo
    Paraules clau: United-states; Pk/pd; Pharmacokinetic; Liposomal amphotericin-b; Liposomal amphotericin b; Invasive candidiasis; Intraabdominal penetration; Intraabdominal candidiasis; Ill patients; Humans; Guidelines; Fungal-infections; Echinocandins; Echinocandin resistance; Decision algorithm; Consensus guidelines; Candidiasis, invasive; Candidemia; Antifungal therapy; Antifungal stewardship; Antifungal stewardshi; Antifungal agents; Abdominal candidiasis
    Resum: BackgroundRegardless of the available antifungals, intraabdominal candidiasis (IAC) mortality continues to be high and represents a challenge for clinicians.Main bodyThis opinion paper discusses alternative antifungal options for treating IAC. This clinical entity should be addressed separately from candidemia due to the peculiarity of the required penetration of antifungals into the peritoneal cavity. Intraabdominal concentrations may be further restricted in critically ill patients where pathophysiological facts alter normal drug distribution. Echinocandins are recommended as first-line treatment in guidelines for invasive candidiasis. However, considering published data, our pharmacodynamic analysis suggests the required increase of doses, postulated by some authors, to attain adequate pharmacokinetic (PK) levels in peritoneal fluid. Given the limited evidence in the literature on PK/PD-based treatments of IAC, an algorithm is proposed to guide antifungal treatment. Liposomal amphotericin B is advocated as first-line therapy in patients with sepsis/septic shock presenting candidemia or endophthalmitis, or with prior exposure to echinocandins and/or fluconazole, or with infections by Candida glabrata. Other situations and alternatives, such as new compounds or combination therapy, are also analysed.ConclusionThere is a critical need for more robust clinical trials, studies examining patient heterogeneity and surveillance of antifungal resistance to enhance patient care and optimise treatment outcomes. Such evidence will help refine the existing guidelines and contribute to a more personalised and effective approach to treating this serious medical condition. Meanwhile, it is suggested to broaden the consideration of other options, such as liposomal amphotericin B, as first-line treatment until the results of the fungogram are available and antifungal stewardship could be implemented to prevent the development of resistance.
    Àrees temàtiques: Saúde coletiva; Nutrição; Medicina veterinaria; Medicina iii; Medicina ii; Medicina i; Interdisciplinar; Farmacia; Engenharias iv; Enfermagem; Educação física; Critical care medicine; Critical care and intensive care medicine; Ciências biológicas iii; Ciências biológicas ii; Ciências biológicas i; Ciência de alimentos; Biotecnología
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: alejandrohugo.rodriguez@urv.cat
    Data d'alta del registre: 2025-01-27
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://ccforum.biomedcentral.com/articles/10.1186/s13054-023-04673-6
    Referència a l'article segons font original: Critical Care. 27 (1): 382-
    Referència de l'ítem segons les normes APA: Maseda, Emilio; Martin-Loeches, Ignacio; Zaragoza, Rafael; Peman, Javier; Fortun, Jesus; Grau, Santiago; Aguilar, Gerardo; Varela, Marina; Borges, Mar (2023). Critical appraisal beyond clinical guidelines for intraabdominal candidiasis. Critical Care, 27(1), 382-. DOI: 10.1186/s13054-023-04673-6
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI de l'article: 10.1186/s13054-023-04673-6
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2023
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Critical Care and Intensive Care Medicine,Critical Care Medicine
    United-states
    Pk/pd
    Pharmacokinetic
    Liposomal amphotericin-b
    Liposomal amphotericin b
    Invasive candidiasis
    Intraabdominal penetration
    Intraabdominal candidiasis
    Ill patients
    Humans
    Guidelines
    Fungal-infections
    Echinocandins
    Echinocandin resistance
    Decision algorithm
    Consensus guidelines
    Candidiasis, invasive
    Candidemia
    Antifungal therapy
    Antifungal stewardship
    Antifungal stewardshi
    Antifungal agents
    Abdominal candidiasis
    Saúde coletiva
    Nutrição
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    Farmacia
    Engenharias iv
    Enfermagem
    Educação física
    Critical care medicine
    Critical care and intensive care medicine
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciência de alimentos
    Biotecnología
  • Documents:

  • Cerca a google

    Search to google scholar